MKI67 and neoplasm: Patients from both cohorts with a tumor Ki67 < 10% will continue receiving study treatment for a total of six cycles; those with a persistent Ki67 ≥ 10% will permanently discontinue study treatment and start neoadjuvant CT or receive surgery [28].